Upregulation of Endogenous HMOX1 Expression by a Computer-Designed Artificial Transcription Factor by Guo, Hongfeng et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 168689, 7 pages
doi:10.1155/2010/168689
Research Article
Upregulation of Endogenous HMOX1 Expression by
a Computer-Designed Artiﬁcial Transcription Factor
Hongfeng Guo,1 Yi Tian,2 Hai Lu,1 Yong Wei,1 and DajunYing1
1Department of Anatomy, Third Military Medical University, Gao-Tan-Yan Street, Sha-Ping-Ba District, Chongqing 400038, China
2Department of Immunology, Third Military Medical University, Gao-Tan-Yan Street, Sha-Ping-Ba District,
Chongqing 400038, China
Correspondence should be addressed to Dajun Ying, ydj96@yahoo.com.cn
Received 1 March 2010; Revised 25 May 2010; Accepted 17 June 2010
Academic Editor: Kostas Iatrou
Copyright © 2010 Hongfeng Guo et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Heme oxygenase-1 (HO-1) is well known as a cytoprotective factor. Research has revealed that it is a promising therapeutic target
for cardiovascular diseases. In the current study, an HMOX1 (HO-1 gene) enhancer-speciﬁc artiﬁcial zinc-ﬁnger protein (AZP)
was designed using bioinformatical methods. Then, an artiﬁcial transcription factor (ATF) was constructed based on the AZP. In
the ATF, the p65 functional domain was used as the eﬀector domain (ED), and a nuclear localization sequence (NLS) was also
included. We next analyzed the aﬃnity of the ATF to the HMOX1 enhancer and the eﬀect of the ATF on endogenous HMOX1
expression. The results suggest that the ATF could eﬀectively upregulate endogenous HMOX1 expression in ECV304 cells. With
further research, the ATF could be developed as a potential drug for cardiovascular diseases.
1.Introduction
Heme oxygenase-1 (HO-1) catalyzes the rate-limiting reac-
tion in heme degradation (the oxidative cleavage of heme to
yield carbon monoxide, free iron, and biliverdin). Besides
directly eliminating heme, HO-1 plays a cytoprotective
role via its catalytic products with antioxidant, anti-
inﬂammatory, antiapoptotic, and cell-signaling properties
[1]. Research has revealed that HMOX1 is a cardiovascular
system protective gene, which could be adopted as a thera-
peutic target [2–8].
Artiﬁcial transcription factor (ATF) technology is based
on the resemblance to natural transcription factors [9]. An
ATF consists of a DNA-binding domain (DBD) and an
eﬀector domain (ED). It is well known that an ED retains its
function when fused to other DBDs [10]. Thus, to construct
a desired ATF, the key work is to construct an appropriate
DBD. The Cys2-His2 zinc ﬁnger protein, which is composed
of several zinc ﬁnger motifs, is ubiquitous among natural
transcription factors and the most widely used DBD in
ATF technology [11]. A single zinc ﬁnger motif consists
of approximately 30 amino acids, with a simple ββα fold
stabilizedbyhydrophobicinteractionsandchelationofazinc
ion. Presentation of the α-helix into the major groove of
DNA allows for recognition to a base-pair triplet. Variation
of the speciﬁcity-related amino acid residues in the α-helix
always changes target speciﬁcity of the zinc ﬁnger motif.
Phage display technology has played a major role in
selecting artiﬁcial zinc-ﬁnger proteins (AZPs) with highest
speciﬁcity and aﬃnity in the past decade [12]. However,
the tedious and time-consuming procedure is a problem.
The one-to-one relationship between base-pair triplets and
speciﬁcity-related amino acid residues could be summarized
as a “recognition code table,” which suggests the possibility
fortheAZPrationaldesign[13].Withtherapiddevelopment
of bioinformatics, researchers have paid more and more
attention to this novel method. In the current study, we
designed an HMOX1 enhancer-speciﬁc AZP by ZF tools 3.0
[14], which is an online server based on the “recognition
code table”. Then, we constructed an ATF based on the
AZP and conﬁrmed that it could upregulate endogenous
HMOX1 expression in ECV304 cells. We demonstrated that
theapplicationofbioinformaticsinATFtechnologyprovides
a facile way to upregulate HMOX1 expression. This method
could probably be applied to other disease-related genes as
well.2 Journal of Biomedicine and Biotechnology
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TGTTTCCTGAAGGCGCCTTGGGAATGCTGAGTCGCGATTT
CCTCATCCCCTCGTGCAGCTGCATTTCTGCTGCGTCATGT
TTGGGAGGGGGGACTCGCGGAAACAAAGGGAAGGCGGATT
TTGCTAGATTTTGCTGAGTCACCAGTGCCTCCTCAGCTTC
TCTTTAGGTGGGAGGTGAAAGGGCAGCTTTAATGGTAGGC
Figure 1: The DNA sequence selected for prescreening. A 54bp
DNA sequence between the two stress response elements (StREs) of
human HMOX1 enhancer (underlined) was selected for prescreen-
ing.
2.MaterialsandMethods
2.1. ZF Tools 3.0 Designing. ZF tools 3.0 (http://www.scripps
.edu/mb/barbas/zfdesign/zfdesignhome.php)i saw e b s i t e
which provides several tools for selecting zinc ﬁnger protein
(ZFP) target sites and for designing the proteins that will
target them [14]. In the current study, the ﬁrst two tools
(“Search DNA Sequence for Contiguous or Separated Target
Sites” and “Design a Zinc Finger Protein”) were explored.
The sequence between the two stress response elements
(StREs) of human HMOX1 enhancer was submitted to ZF
tools 3.0 to search AZP target sites (Figure 1). Parameter
settings are (1) “Triplets to search” included all available
triplets (GNG, GN(ACT), ANN, CNN, and TNN). (2) “ZF
set” was “total” and “Contiguous targets” radio button was
selected. (3) “Minimum target size” was “18”. After that,
several candidate target sites were found.
Due to the large number of target sites that ZF Tools 3.0
may identify, four scoring functions (“Base”, “XNN”, “GNN”,
and “GACT”) were implemented to assist users in selecting
promisingtargetsites.AsaruleinZFTools3.0,thehigherthe
score, the better. However, diﬀerent scoring functions may
generate conﬂicting results. In the current study, the “Base”
function, which uses data from ELISA speciﬁcity graphs in
order to predict the total number of oﬀ-target sites that a
given ZFP may recognize, was used since it was the most
sophisticated function. In addition, the target site overlap
(TSO) interaction may decrease the independent modularity
of the triplets and thereby should be avoided. According to
these principles, the sequence with the top score and without
TSO was selected as the best target site for the AZP, which
was then submitted to ZF tools 3.0 again to obtain the amino
acid sequence of the corresponding AZP.
2.2. SWISS-MODEL Assessing. SWISS-MODEL (http://swi-
ssmodel.expasy.org/)i saf u l l ya u t o m a t e dp r o t e i ns t r u c t u r e
homology-modeling server which provides multiple tools
for protein modeling [15–17]. In the current study, the
amino acid sequence of the AZP was submitted to
“Sequence Feature Scan” (http://swissmodel.expasy.org/
space/index.php?func=tools sequencescan1) for secondary
structure prediction, prediction of disordered regions,
and assignment of domains in the target sequence. The
sequence was then submitted to “Automated Modeling
Mode” (http://swissmodel.expasy.org/workspace/index.php?
func=modelling simple1) for homology modeling. After
that,“Anolea”[18]and“Verify3D”[19]optionswereselected
forassessingthepackingqualityandthestructureoftheAZP.
2.3. ATF Vector Construction. The DNA coding sequence
of the AZP was optimized and synthesized by Shang-
hai Sangon. Then, it was cloned into the PUC57 vector
to obtain PUC57-AZP. The pcDNA3.1-NLS-eGFP-p65-ﬂag
vector,whichcontainsthecodingsequencesofthefunctional
domainofp65(whichwasusedfortheeﬀectordomaininthe
current study) and the nuclear localization sequence (NLS)
(CCCAAGAAGAAGAGGAAGGTG), was a kind gift from
Dr. Philip Gregory (Sangamo BioSciences). PUC57-AZP
and pcDNA3.1-NLS-eGFP-p65-ﬂag were double digested by
restriction endonucleases KpnI (AﬂII) and BamHI to obtain
the AZP and NLS-p65-ﬂag (p65-ﬂag) fragments. The two
fragments were then recombined to construct pcDNA3.1-
NLS-AZP-p65-ﬂag (pcDNA3.1-AZP-p65-ﬂag), which was
regarded as the ATF vector (Figure 2). The two ATF vectors
with or without NLS were subsequently veriﬁed by DNA
sequencing.
2.4. Cell Culture and Transfection. In the current study,
ECV304 cell line was used for intracellular tests. ECV304
cell line was regarded as a human endothelial cell line
before. However, recent DNA proﬁling and cytogenetic
studies showed that it was a derivative of the T24 bladder
carcinoma [20] .E C V 3 0 4c e l l sw e r ec u l t u r e di nD M E M
(high glucose) containing 10% FBS and ZnCl2 (0.1mM)
under a humidiﬁed atmosphere of 5% CO2 and 95% air
at 37
◦C. For transfection, cells were cultured in plates 1
day before and transfected using the Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. PUC57-AZP (regarded as the AZP
vector), pcDNA3.1-NLS-eGFP-p65-ﬂag (regarded as the p65
vector), and pcDNA3.1-azp∗-p65- ﬂag or pcDNA3.1-NLS-
azp∗-p65-ﬂag (ATF vectors constructed by our group for
another gene [21], regarded as the control ATF vectors) were
used as control vectors according to experimental needs.
2.5. Immunoﬂuorescence. The ECV304 cells transfected with
ATF vectors were ﬁxed with 4% paraformaldehyde in
phosphate-buﬀered saline (PBS) and then permeabilized
with 0.5% Triton X-100 in PBS for 10 minutes. After
rinsing 3 times with PBS, the cells were incubated in goat
serum (1:50 in PBS) for 20 minutes. This was followed by
incubation of mouse antiﬂag monoclonal antibody (1:1000
in PBS) for 12 hours. The resulting cells were rinsed 3 times
with PBS again and ﬁnally incubated with goat antimouse
IgG, Cy3 conjugate (1:200 in PBS) for 30 minutes. The
antibodies were purchased from Boster (Wuhan, China).
The resulting cells were then stained with 4,6-diamidino-
2- phenylindole dihydrochloride (DAPI) (Sigma) solution
(100ng/ml in PBS) and ﬁnally mounted in 70% glycerol
in PBS containing 2.5% 1,4-diazabicyclo [2.2.2] octaneJournal of Biomedicine and Biotechnology 3
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Figure 2: Construction of the ATF vectors. PUC57-AZP and pcDNA3.1-NLS-eGFP-p65-ﬂag were double digested at the KpnI (AﬂII) and
BamHI restriction sites respectively to obtain the AZP and pcDNA3.1-p65-ﬂag (pcDNA3.1-NLS-p65-ﬂag) fragments. The two fragments
were then recombined to construct pcDNA3.1-NLS-AZP-p65-ﬂag (pcDNA3.1-AZP-p65-ﬂag) vector.
(DABCO) (Sigma). Fluorescence was analyzed under a Leica
Tcs Sp5 laser scanning confocal microscope.
2.6. Dual-Luciferase Reporter Assay. The ﬁreﬂy-luciferase
reporters were hHO4.9luc and pGL3-control, while the
renilla-luciferase reporter was pRL-TK. The hHO4.9luc
vector, which was constructed by cloning a 4.9kbp SacI-
XhoI fragment (containing the promoter and enhancer
of human HMOX1) into the pGL3 basic vector, was a
kind gift from Professor Norbert Leitinger (University of
Virginia, VA, USA) [22]. The pGL3-control vector con-
tains SV40 promoter and enhancer sequences, resulting in
strong expression of ﬁreﬂy luciferase in many types of
mammalian cells (including ECV304 cells). The candidate
vectors were pcDNA3.1-AZP-p65-ﬂag, pcDNA3.1- NLS-
AZP-p65-ﬂag, PUC57-AZP, pcDNA3.1-NLS-eGFP-p65-ﬂag,
and pcDNA3.1-azp∗-p65-ﬂag. For each of the vectors, four
dose gradients (0, 50ng, 100ng, and 150ng) were used.
PcDNA3.1 was added to each gradient to reach 200ng
so as to normalize the transfection eﬃciency. Tritrans-
fection of the candidate vector, ﬁreﬂy-luciferase reporter,
and renilla- luciferase reporter were performed on ECV304
cells, which were cultured in 96-well plates. Forty-eight
hours after transfection, the dual-luciferase reporter assay
was performed using a Dual-Lucy Assay Kit (Vigorous,
Beijing, China), according to the protocol provided by the
manufacturer.LuminescenceintensitywasmeasuredbyaTD
20/20 Luminometer (Promega, Madison, WI, USA).
2.7. Quantitative Real-Time RT-PCR. Transfections were
performed on ECV304 cells, which were cultured in
12-well plates. The candidate vectors were pcDNA3.1-
AZP-p65-ﬂag, pcDNA3.1-NLS-AZP- p65-ﬂag, PUC57-AZP,
pcDNA3.1-NLS-eGFP-p65-ﬂag, and pcDNA3.1-NLS-azp∗-
p65-ﬂag. For each of the vectors, four dose gradients (0.5μg,
1.0μg, 1.5μg, and 2.0 μg) were used. PcDNA3.1 was added
to each gradient to reach 2.0 μg so as to normalize the
transfection eﬃciency. Forty-eight hours after transfection,
the total RNA was isolated using Trizol reagent (Invitrogen).
Total RNA (0.5 μg)wasusedforreversetranscriptionat37
◦C
for 15 minutes and 85
◦C for 5 seconds. After denaturing
at 95
◦C for 10 seconds, PCR was conducted for 40 cycles
at 95
◦Cf o r5s e c o n d s ,5 5
◦C for 15 seconds, and 60
◦C
for 20 seconds. Real-time PCR was performed using a
SYBR PrimeScript RT-PCR Kit (Takara, Shiga, Japan) on
a Rotor-Gene 6000 (Gene Company Limited, Hong Kong),
according to the protocol provided by the manufacturers.
The primers were designed by Primer Premier 5.0 (forward:
5 -ATGACACCAAGGACCAGAGCC-3 ;r e v e r s e :5  -GTAAG
GACCCATCGGAGAAGC-3 ) and were then synthesized at
Shanghai Sangon. The ampliﬁed product was a 151bp
fragment of HMOX1 cDNA. Human GAPDH was used as
the internal control to normalize the results. The GAPDH
primers were purchased from Takara (Takara Code D3790,
Primer set ID HA067812, GenBank Acc. NM 002046). The
data were analyzed by Rotor-Gene analysis software.
3. Results and Discussion
3.1. Design of the HMOX1 Enhancer-Speciﬁc AZP. We used
the 54bp DNA sequence between the two StREs of human
HMOX1 enhancer for prescreening (Figure 1). After submit-
ting it to ZF tools 3.0, 12 possible target sites were obtained
(Table 1) .T h es e q u e n c e( 4 )5  -ACT CGC GGA AAC AAA
GGG-3 , with the second highest score while without TSO,
was selected as the best target site for the AZP.
The accessibility of genomic DNA in chromatin to
ATFs is very important [23]. Targeting a genomic region
around known cis-elements that are accessible by native
transcription factors is a good choice when information on
the chromatin structures of target genes is not available [24].
Extensive analysis of the mouse gene, and to a lesser extent
the human gene, has identiﬁed a common mechanism (the
StRE/Nrf2 transcription factor pathway) for gene regulation
in response to a diverse array of HO-1 inducers [25]. In
addition, the StREs were excluded for relative speciﬁcity,
since the StRE/Nrf2 transcription factor pathway is also
involved in the regulation of some other stress-related genes.
The sequence (4) 5 -ACT CGC GGA AAC AAA GGG-
3  was submitted to ZF tools 3.0 again to obtain the amino
acid sequence of the corresponding AZP (Figure 3). As
a result of “Sequence Feature Scan”, “InterproScan” [26]
showed that the AZP consisted of six Cys2-His2 zinc ﬁnger
motifs, which were located at the 8–30, 36–58, 64–86, 92–
114, 120–142, and 148–170 amino acid residues of the AZP.
“Secondary Structure & Disorder prediction” showed the
assignment of domains in the AZP and indicated that there
werefewdisorderedregionsintheAZP.Homologymodeling4 Journal of Biomedicine and Biotechnology
Table 1: Details of the 12 possible target sites for the AZP.
Target Score (Base function) TSO Issues
(1) 5 -GGA GGG GGG ACT CGC GGA-3  52.95 Yes
(2) 5 -GGG GGG ACT CGC GGA AAC-3  56.51 Yes
(3) 5 -GGG ACT CGC GGA AAC AAA-3  56.18 Yes
(4)5
 -ACTCGCGGA AACAAAGGG-3
  56.18 No
(5) 5 -CGC GGA AAC AAA GGG AAG-3  54.35 Yes
(6) 5 -GGA AAC AAA GGG AAG GCG-3  52.08 Yes
(7) 5 -AAC AAA GGG AAG GCG GAT-3  55.03 Yes
(8) 5 -GCG GAA ACA AAG GGA AGG-3  52.26 No
(9) 5 -GAA ACA AAG GGA AGG CGG-3  54.03 No
(10) 5 -ACA AAG GGA AGG CGG ATT-3  54.43 No
(11) 5 -CGG AAA CAA AGG GAA GGC-3  54.19 No
(12) 5 -AAA CAA AGG GAA GGC GGA-3  51.03 No
YKCPECGKSFS RSDKL VR HQRTH TGEKP YKCPECGKSFS QRANL
RA HQRTH TGEKP YKCPECGKSFS DSGNLRV HQRTH TGEKP YKCPECGKSFS Q
RAHLER HQRTH TGEKP YKCPECGKSFS HTGHLLE HQRTH TGEKP YKCPECGK
SFS THLDLIR HQRTH
N-term fixed Helix C-term backbone Zink finger linker C-term fixed N-term backbone
N -LEPGEKP
TGKKTS-C 
Figure 3: The 176 amino acid sequence of the AZP. Diﬀerent Motifs were shown by distinct background colors.
showed the conformation of the six zinc ﬁnger motifs. The
modeling was based on the template 2i13A (a stable AZP).
The sequence identity was 79.221%, and the E-value was
1.26e−44.ToeachaminoacidresidueoftheAZP,theAnolea
value was negative and the Verify 3D value ranged from 0 to
+1. Taken together, these results suggested that the AZP was
quite stable and justiﬁed further experiments.
3.2. Construction of the ATF Vectors. The ﬂag tag on the
ATF vectors was used for protein expression detection.
Immunoﬂuorescence showed that the ECV304 cells, which
were transfected with ATF vectors, were Cy3-positive,
whereas the control cells were not (Figure 4). This indicated
that after vector transfection, the ATF could be normally
expressed in ECV304 cells.
An NLS targets the protein to the cell nucleus through
the nuclear pore complex and directs a newly synthesized
protein into the nucleus via its recognition by cytosolic
nuclear transport receptors. The expressed pcDNA3.1-NLS-
AZP-p65-ﬂag (ATF vector with NLS) was mainly located
in the nuclei, while the expressed pcDNA3.1-AZP-p65-
ﬂag (ATF vector without NLS) was mainly located in the
cytoplasm.However,thelattercouldstillbefoundwithinthe
nuclei. These ﬁndings are further discussed below.
3.3. Aﬃnity of the ATF to HMOX1 Enhancer. In order to
assess the aﬃnity of the ATF to HMOX1 enhancer, a dual-
luciferase reporter assay was performed. HHO4.9luc and
pGL3-control were used as the ﬁreﬂy-luciferase reporter. In
the hHO4.9luc group, for the ATF vectors, a larger dose
resulted in a higher luminescence intensity ratio (LIR). At
50ng, 100ng, and 150ng vector dose, the LIR of pcDNA3.1-
AZP-p65-ﬂag was 1.88-, 2.71-, and 4.00-fold above control,
while that of pcDNA3.1-NLS-AZP-p65-ﬂag was 2.04-, 2.67-
, and 3.88-fold above control (Figure 5(a)). Here, the “fold
above control” represented ratios of the LIR of the ECV304
cells transfected with diﬀerent candidate vectors to that
of the ECV304 cells transfected with pcDNA3.1 (control).
There were no signiﬁcant diﬀerences between the two
ATF vector groups, indicating that the ATF without NLS
could also enter the nuclei (which was consistent with the
immunoﬂuorescence results) and upregulate the reporter
gene expression. This may be attributed to the N
 -terminal
of the p65 functional domain, which acts as an NLS in NF-
κB. For the three control vectors, LIR showed no signiﬁcant
diﬀerence among each dose gradient. In the pGL3-control
group,LIRshowednosigniﬁcantdiﬀerenceamongeachdose
gradient for the ﬁve candidate vectors (Figure 5(b)).
It is well known that the DBD recognizes a particular
region of the DNA, while the ED recruits other proteins of
the transcription machinery in the immediate proximity of
the DNA to start transcription [10]. Sometimes the DBD
may repress gene expression by blocking RNA polymerase
movement. However, neither of the two domains alone
regulates gene expression eﬀectively. The results of the dual-
luciferase reporter assay were consistent with the expecta-
tions. It was the HMOX1 enhancer-speciﬁc ATF, rather thanJournal of Biomedicine and Biotechnology 5
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Figure 4: Expression of the ATF in the ECV304 cells. Immunoﬂuorescence was performed, and the resulting cells were observed under
a laser scanning confocal microscope. (a) ECV304 cells transfected with pcDNA3.1-NLS-AZP-p65-ﬂag. (b) ECV304 cells transfected with
pcDNA3.1-AZP-p65-ﬂag. (c) ECV304 cells transfected with the control plasmids. The white arrows pointed the expressed proteins which
were located in the nuclei.
the AZP or the p65 functional domain alone, that recognized
the HMOX1 enhancer and upregulated the reporter gene
expression.
3.4. Eﬀect of the ATF on Endogenous HMOX1 Expression. It
was reported that ATF which exhibited good performance
in transient reporter assays did not eﬀectively modulate
the endogenous gene expression [23]. This indicated that
the chromatin structures of promoters in reporter plas-
mids were diﬀerent from those in actual chromosomes.
In order to assess the eﬀect of the ATF on endogenous
HMOX1 expression, quantitative real-time RT-PCR was
performed. The control vectors were pcDNA3.1-NLS-eGFP-
p65-ﬂag, PUC57-AZP, and pcDNA3.1-NLS-azp∗-p65-ﬂag.
Experiments were still done on ECV304 cells rather than6 Journal of Biomedicine and Biotechnology
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Figure 5: Aﬃnity of the ATF to HMOX1 enhancer. Dual-luciferase reporter assay was performed; the candidate vectors were pcDNA3.1-
AZP-p65-ﬂag (AZP-p65), pcDNA3.1-NLS-AZP-p65-ﬂag (NLS-AZP-p65), PUC57-AZP (AZP), pcDNA3.1-NLS-eGFP-p65-ﬂag (p65), and
pcDNA3.1- azp∗-p65-ﬂag (azp∗-p65). For each of the vectors, four dose gradients (0, 50ng, 100ng, and 150ng) were used. The ﬁreﬂy-
luciferase reporters were (a) hHO4.9luc and (b) pGL3-control, respectively. The data represent the means ± S.D.
endothelial cell lines (such as HUVECs). This was because
HMOX1 was basically expressed in most human cell lines
(including ECV304 cells), and ECV304 cells were easy to
culture. In the current study, it was a convincing cell line
for testing the eﬀect of the ATF on endogenous HMOX1
expression.
For ATF vectors, HMOX1 mRNA levels increased with
the vector dose, and a dose-response relationship existed.
At 0.5μg, 1.0μg, 1.5μg, and 2.0μg, HMOX1 mRNA of the
pcDNA3.1-AZP-p65-ﬂag group was 3.19-, 4.06-, 4.75-, and
5.91-fold above control, while that of the pcDNA3.1-NLS-
AZP-p65-ﬂag group was 4.71-, 5.90-, 9.12-, and 10.28-fold
above control (Figure 6). Here, the “fold above control”
representedratiosoftheHMOX1mRNAleveloftheECV304
cellstransfectedwithdiﬀerentcandidatevectorstothatofthe
ECV304cellstransfectedwithpcDNA3.1(control).Diﬀerent
from the dual-luciferase reporter assay results, the ATF with
N L Ss e e m e dt ob em o r ee ﬃcient than that without NLS
in upregulating endogenous HMOX1 expression. This may
be attributed to the diﬀerences in the nature of the two
assays. In contrast, the three control vectors failed to raise
HMOX-1 mRNA levels at any dose gradient. These indicated
that the HMOX1 enhancer-speciﬁc ATF could upregulate
endogenous HMOX1 expression, as expected. The ATF with
NLS was more eﬃcient than that without NLS.
In the current study, the p65 functional domain was
used as the ED. In addition, other activation domains, such
as VP16, VP64, p65, S3H, and (FDTDL)11, may also be
considered and may result in a more potent ATF. Moreover,
repressor domains, such as KRAB, SID, ERD, vErbA, and
SRDX fused to the HMOX1 enhancer-speciﬁc AZP, should
prevent HMOX1 from activation [27]. However, these
repressordomainsshouldbeveriﬁedbyfurtherexperiments.
Most human diseases can be treated by activating or
repressing endogenous gene expression. Thus, ATF technol-
ogy has extensive therapeutic applications. It diﬀers from
many novel methods, such as RNA interference or antisense
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Figure 6: Eﬀect of the ATF on endogenous HMOX1 expression.
Quantitative real-time RT-PCR was performed; the candidate
vectors were pcDNA3.1-AZP-p65-ﬂag (AZP-p65), pcDNA3.1-NLS-
AZP-p65-ﬂag (NLS-AZP-p65), PUC57-AZP (AZP), pcDNA3.1-
NLS-eGFP-p65-ﬂag (p65), and pcDNA3.1-NLS-azp∗-p65-ﬂag
(NLS-azp∗-p65). For each of them, four dose gradients (0.5μg,
1.0μg, 1.5μg, and 2.0μg) were used. The data represent the means
± S.D.
technology, for it can be used for the gene expression
upregulation rather than exclusively for its downregulation
[28]. Our work has shown that an HMOX1 enhancer-
speciﬁc AZP could be readily designed by bioinformatical
methods. By fusing the AZP to the p65 functional domain
withanNLS,theresultingATFcouldupregulateendogenous
HMOX1 expression in ECV304 cells. This approach provides
a facile way to modulate endogenous gene expression. It
can be applied to other disease-related genes as well. We
believe that with further research aimed at selecting the most
potent activation domain and acquiring the cell-penetratingJournal of Biomedicine and Biotechnology 7
protein, the ATF could be developed as a potential drug for
cardiovascular diseases.
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